Pharmacogenomics and cardiovascular disease

Emily K. Dornblaser; Craig P. Worby; Daniel Alan Brazeau

doi:10.4018/978-1-5225-7122-3.ch010

Pharmacogenomics and cardiovascular disease

Emily K. Dornblaser
, Craig P. Worby
, Daniel Alan Brazeau

Pharmaceutical Sciences

University of New England

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Cardiovascular disease is one of the most prevalent disease states in the U.S. and contributes substantially to overall morbidity and mortality. The ability to effectively optimize the treatment of cardiovascular disease has a significant impact on overall disease prevention and treatment. This chapter discusses the relationship between genetic variations and their impact on medications used for the treatment of cardiovascular disorders. Key medications that are susceptible to genetic variation have been identified. The chapter describes the mechanisms by which genetic variation may contribute to altered medication concentrations or effects and briefly reviews the place in therapy for the cardiovascular medications. In addition, this chapter reviews current clinical literature to determine the overall impact these variations may have on clinical outcomes.

Original language	English
Title of host publication	Chronic Illness and Long-Term Care
Subtitle of host publication	Breakthroughs in Research and Practice
Publisher	IGI Global
Pages	184-197
Number of pages	14
Volume	1
ISBN (Electronic)	9781522571230
ISBN (Print)	1522571221, 9781522571223
DOIs	https://doi.org/10.4018/978-1-5225-7122-3.ch010
State	Published - Jan 1 2018

Access to Document

10.4018/978-1-5225-7122-3.ch010

Cite this

@inbook{399683f705964938afe99d28c05024cd,

title = "Pharmacogenomics and cardiovascular disease",

abstract = "Cardiovascular disease is one of the most prevalent disease states in the U.S. and contributes substantially to overall morbidity and mortality. The ability to effectively optimize the treatment of cardiovascular disease has a significant impact on overall disease prevention and treatment. This chapter discusses the relationship between genetic variations and their impact on medications used for the treatment of cardiovascular disorders. Key medications that are susceptible to genetic variation have been identified. The chapter describes the mechanisms by which genetic variation may contribute to altered medication concentrations or effects and briefly reviews the place in therapy for the cardiovascular medications. In addition, this chapter reviews current clinical literature to determine the overall impact these variations may have on clinical outcomes.",

author = "Dornblaser, \{Emily K.\} and Worby, \{Craig P.\} and Brazeau, \{Daniel Alan\}",

note = "Publisher Copyright: {\textcopyright} 2019, IGI Global.",

year = "2018",

month = jan,

day = "1",

doi = "10.4018/978-1-5225-7122-3.ch010",

language = "English",

isbn = "1522571221",

volume = "1",

pages = "184--197",

booktitle = "Chronic Illness and Long-Term Care",

publisher = "IGI Global",

}

TY - CHAP

T1 - Pharmacogenomics and cardiovascular disease

AU - Dornblaser, Emily K.

AU - Worby, Craig P.

AU - Brazeau, Daniel Alan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cardiovascular disease is one of the most prevalent disease states in the U.S. and contributes substantially to overall morbidity and mortality. The ability to effectively optimize the treatment of cardiovascular disease has a significant impact on overall disease prevention and treatment. This chapter discusses the relationship between genetic variations and their impact on medications used for the treatment of cardiovascular disorders. Key medications that are susceptible to genetic variation have been identified. The chapter describes the mechanisms by which genetic variation may contribute to altered medication concentrations or effects and briefly reviews the place in therapy for the cardiovascular medications. In addition, this chapter reviews current clinical literature to determine the overall impact these variations may have on clinical outcomes.

AB - Cardiovascular disease is one of the most prevalent disease states in the U.S. and contributes substantially to overall morbidity and mortality. The ability to effectively optimize the treatment of cardiovascular disease has a significant impact on overall disease prevention and treatment. This chapter discusses the relationship between genetic variations and their impact on medications used for the treatment of cardiovascular disorders. Key medications that are susceptible to genetic variation have been identified. The chapter describes the mechanisms by which genetic variation may contribute to altered medication concentrations or effects and briefly reviews the place in therapy for the cardiovascular medications. In addition, this chapter reviews current clinical literature to determine the overall impact these variations may have on clinical outcomes.

UR - https://www.scopus.com/pages/publications/85059729343

U2 - 10.4018/978-1-5225-7122-3.ch010

DO - 10.4018/978-1-5225-7122-3.ch010

M3 - Chapter

AN - SCOPUS:85059729343

SN - 1522571221

SN - 9781522571223

VL - 1

SP - 184

EP - 197

BT - Chronic Illness and Long-Term Care

PB - IGI Global

ER -

Pharmacogenomics and cardiovascular disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this